## Metabolic Bone Disease in Chronic Kidney Disease **Key Point:** The pathophysiology of CKD-MBD (mineral and bone disorder) is multifactorial and involves dysregulation of phosphate handling, vitamin D metabolism, and PTH regulation. Understanding which mechanisms are active at which CKD stage is essential. ### Phosphate Handling in CKD **High-Yield:** FGF23 (fibroblast growth factor 23) is the PRIMARY phosphaturic hormone in early CKD. In CKD stage 3b, FGF23 levels are **elevated**, not reduced. FGF23 increases in response to hyperphosphatemia and acts on the proximal tubule to increase phosphate excretion and suppress 1α-hydroxylase (reducing calcitriol production). Hyperphosphatemia in CKD stage 3b occurs because: 1. Decreased glomerular filtration of phosphate (reduced GFR) 2. Despite elevated FGF23, phosphate retention still occurs 3. The kidney's ability to respond to FGF23 is progressively impaired in advanced CKD **Option 0 (INCORRECT):** States that FGF23 responsiveness is reduced in CKD stage 3b. While this becomes true in very advanced CKD (stage 5), in stage 3b the problem is primarily **reduced GFR** with FGF23 still elevated and partially responsive. The statement conflates the mechanism — it's GFR loss, not FGF23 unresponsiveness, that drives hyperphosphatemia at this stage. ### Correct Statements Explained **Option 1 (Calcitriol synthesis):** In CKD, the proximal tubule loses 1α-hydroxylase activity due to: - Direct effects of uremia and hyperphosphatemia - Suppression by FGF23 - Reduced substrate availability (25-OH vitamin D) This leads to calcitriol deficiency, contributing to hypocalcemia and secondary hyperparathyroidism. ✓ TRUE **Option 2 (Calcium-based binders):** Calcium-based phosphate binders (calcium carbonate, calcium acetate) increase serum calcium and risk vascular calcification, especially in CKD stage 3b–5. Non-calcium binders (sevelamer, lanthanum carbonate) or iron-based binders (ferric citrate) are preferred. ✓ TRUE **Option 3 (PTH elevation):** Secondary hyperparathyroidism develops due to: - Hypocalcemia (from calcitriol deficiency) - Hyperphosphatemia (direct stimulus to PTH secretion) - Reduced FGF23-mediated PTH suppression - Parathyroid gland hyperplasia PTH levels are markedly elevated in CKD-MBD. ✓ TRUE **Clinical Pearl:** The progression of CKD-MBD follows a predictable sequence: FGF23 rises early (stage 2–3) → calcitriol falls → PTH rises → hyperphosphatemia worsens → vascular calcification risk increases. Early intervention with phosphate restriction and vitamin D supplementation (where appropriate) can slow progression. **Mnemonic:** **CHOP** — Calcitriol ↓, Hyperphosphatemia ↑, Osteitis fibrosa, PTH ↑↑ (in secondary hyperparathyroidism).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.